Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Clinical Roundup

Yale researchers identify accelerated genetic aging in breast tissue adjacent to breast cancer tumors

April 01, 2022
Vol.48 No.13
Drugs & Targets

Paige launches AI software to enable accurate and efficient detection of breast cancer metastases in lymph nodes

April 01, 2022
Vol.48 No.13
Carol Fabian on breast cancer prevention and tissue sampling using fine needle aspiration
Cancer History ProjectConversation with The Cancer LetterFree

Carol Fabian on breast cancer prevention and tissue sampling using fine needle aspiration

March 25, 2022
Vol.48 No.12
By Alexandria Carolan
Clinical Roundup

Enrollment in TMIST breast cancer screening trial surpasses halfway mark; Black participation rises above 20%

March 25, 2022
Vol.48 No.12
Clinical Roundup

Ribociclib added to endocrine therapy extends survival in postmenopausal metastatic breast cancer patients

March 11, 2022
Vol.48 No.10
In Brief

ACS to establish breast cancer and cervical cancer roundtables

February 18, 2022
Vol.48 No.07
Clinical Roundup

Sanford Burnham Prebys study: Molecular differences help explain higher breast cancer mortality in Black women

February 11, 2022
Vol.48 No.06
In Brief

Mateusz Opyrchal named inaugural Vera Bradley Foundation Scholar in Breast Cancer Discovery at IU

February 04, 2022
Vol.48 No.05
Clinical Roundup

Yale study explores treatment for advanced triple-negative breast cancer

February 04, 2022
Vol.48 No.05
Drugs & Targets

Veru, Eli Lilly to evaluate enobosarm + Verzenio in phase III ENABLAR-2 trial

February 04, 2022
Vol.48 No.05

Posts navigation

Previous1…272829…32Next

Trending Stories

  • HHS Secretary Kennedy’s diet advice is heavy on meat and light on scientific consensus
  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
  • FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
    Draft guidance consolidates trial design updates for developers
  • “This is not about protecting life”: Supreme Court overturn of Roe v. Wade threatens lives of cancer patients, doctors
  • NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account